FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938704617> ?p ?o ?g. }

• W2938704617 endingPage "e623" @default.
• W2938704617 startingPage "e613" @default.
• W2938704617 abstract "The associations between the extent of forced expiratory volume in 1 s (FEV1) impairment and mortality, incident cardiovascular disease, and respiratory hospitalisations are unclear, and how these associations might vary across populations is unknown.In this international, community-based cohort study, we prospectively enrolled adults aged 35-70 years who had no intention of moving residences for 4 years from rural and urban communities across 17 countries. A portable spirometer was used to assess FEV1. FEV1 values were standardised within countries for height, age, and sex, and expressed as a percentage of the country-specific predicted FEV1 value (FEV1%). FEV1% was categorised as no impairment (FEV1% ≥0 SD from country-specific mean), mild impairment (FEV1% <0 SD to -1 SD), moderate impairment (FEV1% <-1 SD to -2 SDs), and severe impairment (FEV1% <-2 SDs [ie, clinically abnormal range]). Follow-up was done every 3 years to collect information on mortality, cardiovascular disease outcomes (including myocardial infarction, stroke, sudden death, or congestive heart failure), and respiratory hospitalisations (from chronic obstructive pulmonary disease, asthma, pneumonia, tuberculosis, or other pulmonary conditions). Fully adjusted hazard ratios (HRs) were calculated by multilevel Cox regression.Among 126 359 adults with acceptable spirometry data available, during a median 7·8 years (IQR 5·6-9·5) of follow-up, 5488 (4·3%) deaths, 5734 (4·5%) cardiovascular disease events, and 1948 (1·5%) respiratory hospitalisation events occurred. Relative to the no impairment group, mild to severe FEV1% impairments were associated with graded increases in mortality (HR 1·27 [95% CI 1·18-1·36] for mild, 1·74 [1·60-1·90] for moderate, and 2·54 [2·26-2·86] for severe impairment), cardiovascular disease (1·18 [1·10-1·26], 1·39 [1·28-1·51], 2·02 [1·75-2·32]), and respiratory hospitalisation (1·39 [1·24-1·56], 2·02 [1·75-2·32], 2·97 [2·45-3·60]), and this pattern persisted in subgroup analyses considering country income level and various baseline risk factors. Population-attributable risk for mortality (adjusted for age, sex, and country income) from mildly to moderately reduced FEV1% (24·7% [22·2-27·2]) was larger than that from severely reduced FEV1% (3·7% [2·1-5·2]) and from tobacco use (19·7% [17·2-22·3]), previous cardiovascular disease (5·5% [4·5-6·5]), and hypertension (17·1% [14·6-19·6]). Population-attributable risk for cardiovascular disease from mildly to moderately reduced FEV1 was 17·3% (14·8-19·7), second only to the contribution of hypertension (30·1% [27·6-32·5]).FEV1 is an independent and generalisable predictor of mortality, cardiovascular disease, and respiratory hospitalisation, even across the clinically normal range (mild to moderate impairment).Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Ontario Ministry of Health and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Servier, and GlaxoSmithKline, Novartis, and King Pharma. Additional funders are listed in the appendix." @default.
• W2938704617 created "2019-04-25" @default.
• W2938704617 creator A5000432967 @default.
• W2938704617 creator A5000489188 @default.
• W2938704617 creator A5005449207 @default.
• W2938704617 creator A5005906845 @default.
• W2938704617 creator A5009091228 @default.
• W2938704617 creator A5011268662 @default.
• W2938704617 creator A5013961443 @default.
• W2938704617 creator A5016735656 @default.
• W2938704617 creator A5018011410 @default.
• W2938704617 creator A5018906092 @default.
• W2938704617 creator A5023361030 @default.
• W2938704617 creator A5024045597 @default.
• W2938704617 creator A5026476319 @default.
• W2938704617 creator A5026568725 @default.
• W2938704617 creator A5028695564 @default.
• W2938704617 creator A5032775000 @default.
• W2938704617 creator A5039145780 @default.
• W2938704617 creator A5041495322 @default.
• W2938704617 creator A5043684388 @default.
• W2938704617 creator A5045264049 @default.
• W2938704617 creator A5045336307 @default.
• W2938704617 creator A5050936489 @default.
• W2938704617 creator A5055200248 @default.
• W2938704617 creator A5055703349 @default.
• W2938704617 creator A5055934466 @default.
• W2938704617 creator A5058694063 @default.
• W2938704617 creator A5064026696 @default.
• W2938704617 creator A5066222424 @default.
• W2938704617 creator A5068719503 @default.
• W2938704617 creator A5069359085 @default.
• W2938704617 creator A5069728608 @default.
• W2938704617 creator A5070771797 @default.
• W2938704617 creator A5072267673 @default.
• W2938704617 creator A5077219405 @default.
• W2938704617 creator A5081195905 @default.
• W2938704617 creator A5081312292 @default.
• W2938704617 creator A5083663995 @default.
• W2938704617 creator A5086287744 @default.
• W2938704617 date "2019-05-01" @default.
• W2938704617 modified "2023-10-18" @default.
• W2938704617 title "Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study" @default.
• W2938704617 cites W1975187245 @default.
• W2938704617 cites W1996515325 @default.
• W2938704617 cites W2009596490 @default.
• W2938704617 cites W2018126138 @default.
• W2938704617 cites W2047519267 @default.
• W2938704617 cites W2058939989 @default.
• W2938704617 cites W2099449365 @default.
• W2938704617 cites W2104222371 @default.
• W2938704617 cites W2118228748 @default.
• W2938704617 cites W2123116809 @default.
• W2938704617 cites W2124879124 @default.
• W2938704617 cites W2138187684 @default.
• W2938704617 cites W2147363553 @default.
• W2938704617 cites W2168315832 @default.
• W2938704617 cites W2171129594 @default.
• W2938704617 cites W2337032743 @default.
• W2938704617 cites W2342547892 @default.
• W2938704617 cites W2344222696 @default.
• W2938704617 cites W2479712677 @default.
• W2938704617 cites W2583741852 @default.
• W2938704617 cites W2614171167 @default.
• W2938704617 cites W2768767566 @default.
• W2938704617 cites W2794312975 @default.
• W2938704617 cites W874769420 @default.
• W2938704617 doi "https://doi.org/10.1016/s2214-109x(19)30070-1" @default.
• W2938704617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31000131" @default.
• W2938704617 hasPublicationYear "2019" @default.
• W2938704617 type Work @default.
• W2938704617 sameAs 2938704617 @default.
• W2938704617 citedByCount "106" @default.
• W2938704617 countsByYear W29387046172019 @default.
• W2938704617 countsByYear W29387046172020 @default.
• W2938704617 countsByYear W29387046172021 @default.
• W2938704617 countsByYear W29387046172022 @default.
• W2938704617 countsByYear W29387046172023 @default.
• W2938704617 crossrefType "journal-article" @default.
• W2938704617 hasAuthorship W2938704617A5000432967 @default.
• W2938704617 hasAuthorship W2938704617A5000489188 @default.
• W2938704617 hasAuthorship W2938704617A5005449207 @default.
• W2938704617 hasAuthorship W2938704617A5005906845 @default.
• W2938704617 hasAuthorship W2938704617A5009091228 @default.
• W2938704617 hasAuthorship W2938704617A5011268662 @default.
• W2938704617 hasAuthorship W2938704617A5013961443 @default.
• W2938704617 hasAuthorship W2938704617A5016735656 @default.
• W2938704617 hasAuthorship W2938704617A5018011410 @default.
• W2938704617 hasAuthorship W2938704617A5018906092 @default.
• W2938704617 hasAuthorship W2938704617A5023361030 @default.
• W2938704617 hasAuthorship W2938704617A5024045597 @default.
• W2938704617 hasAuthorship W2938704617A5026476319 @default.
• W2938704617 hasAuthorship W2938704617A5026568725 @default.
• W2938704617 hasAuthorship W2938704617A5028695564 @default.
• W2938704617 hasAuthorship W2938704617A5032775000 @default.
• W2938704617 hasAuthorship W2938704617A5039145780 @default.
• W2938704617 hasAuthorship W2938704617A5041495322 @default.
• W2938704617 hasAuthorship W2938704617A5043684388 @default.

• next